Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

ViaCell will begin to enroll patients in a Phase I/II clinical trial of CB001, a highly purified population of stem cells that has been isolated from umbilical cord blood and multiplied using the company’s patented Selective Amplification technology.

In The Pipeline